“TINSAL-T2D” is also known as Targeting Inflammation with Salsalate in Type 2 Diabetes. The study of the goal is to further research the medication salsalate, discussed in the October 2008 edition of Diabetes Health. The initial study at the Joslin Diabetes Center in Boston showed the inexpensive aspirin-like drug used to treat arthritis showed a significant reduction in blood glucose levels as well as C-reactive protein, a marker for inflammation.
The “TINSAL-T2D” study, funded by the National Institute of Diabetes and Digestive and Kidney Diseases, is using salsalate to target inflammation. A second study, “TINSAL-IGT,” being performed at the Carl T. Hayden VA Medical Center in Phoenix, is aimed at helping patients with impaired glucose tolerance improve their sensitivity to insulin.
For patients or family members who would like to participate, the one-year study requires the participation of 560 adults from age 18 to 75. Participants must not be using insulin (although one or two oral medications are permissible) and must have poor blood sugar control.
If the medication continues to prove effective against high blood sugar and inflammation, the hope is to add salsalate to the arsenal of diabetes medications. Since physicians have years of experience prescribing the medication for arthritis, it is already known to be inexpensive and safe – something not always the case with newer diabetes medications. In addition, because of the relationship with inflammation, Joslin researchers are also hoping salsalate reduces the occurrence of coronary artery disease among type 2 diabetics.
More study information can be found at www.tinsalt2d.org. The study leader is Allison B. Goldfine, MD and may be reached via e-mail at [email protected].